Multidrug-resistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome

100Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Nosocomial infections caused by Acinetobacter baumannii have increased in recent years. Isolates of multidrug-resistant A.baumannii (MDRAB) have been recovered in Taiwan since 1999. The characteristics of 55 patients with MDRAB bacteraemia infections occurring between January 2003 and February 2005 were analysed retrospectively. The overall 30-day mortality rate was 49%. The portal of entry was identified in 80% of patients, with the respiratory tract being implicated most frequently. Among the different antimicrobial regimens prescribed, the combination of a carbapenem and ampicillin-sulbactam was associated with a better outcome than the combination of a carbapenem and amikacin, or a carbapenem alone. © 2007 European Society of Clinical Microbiology and Infectious Diseases.

Cite

CITATION STYLE

APA

Kuo, L. C., Lai, C. C., Liao, C. H., Hsu, C. K., Chang, Y. L., Chang, C. Y., & Hsueh, P. R. (2007). Multidrug-resistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome. Clinical Microbiology and Infection, 13(2), 196–198. https://doi.org/10.1111/j.1469-0691.2006.01601.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free